A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
A phase 1/2 trial of YL202, Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07169994 by MediLink Therapeutics (Suzhou) Co., Ltd., with 414 participants planned, started 2025-09-02 and due to reach its primary completion in 2026-09-01. Interventions recorded: YL202 for injection; Toripalimab injection, YL202 for injection; Furmonertinib Mesilate Tablets. Conditions listed: Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer
Shares YL202, MediLink Therapeutics, Non-small-cell lung cancer.
- TrialA Study of YL202 in Patients With Advanced Solid Tumors
Shares YL202, MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
Shares YL202, MediLink Therapeutics.
- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Shares MediLink Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
- TrialA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Shares MediLink Therapeutics, Toripalimab.
- TrialA Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
Shares Toripalimab, Small-cell lung cancer, Non-small-cell lung cancer.